Tumour Necrosis Factor-α Inhibition Improves Stroke Outcome in a Mouse Model of Rheumatoid Arthritis

N. R. Bonetti¹, C. Diaz-Cañestro¹, L. Liberale¹, M. Crucet¹, A. Akhmedov¹, M. Merlini³, M. F. Reiner¹, S. Gobbato¹, S. Stivala², G. Kollias¹, F. Ruschitzka⁵, T. F. Lüscher¹, J. H. Beer¹, & G. G. Camici¹

Rheumatoid Arthritis (RA) is a chronic inflammatory disorder where incidence and severity of myocardial infarction are increased. Data on the incidence and outcome of stroke are conflicting. Thus, we investigated outcome after Ischemia/Reperfusion (I/R) brain injury in a mouse model of RA and assessed for the role of the tumour necrosis factor-α (TNF-α) inhibitor Infliximab herein. We used a TNF-α reliant mouse model of RA. RA and wildtype (WT) animals were treated with vehicle (RA/WT) or Infliximab (RA Infliximab) for 4 weeks, before undergoing I/R brain injury. RA-animals displayed larger strokes and poorer neurological performance. Immunohistochemistry on brain sections revealed increased numbers of resident and peripheral innate immune cells (microglia and macrophages); increased Blood-Brain-Barrier (BBB)-disruption; decreased levels of the tight junction proteins (TJPs) claudin-5 and occludin; increased expression of matrix-metalloproteinases (MMP)-3 and -9 and enhanced lipid peroxidation. Treatment with Infliximab corrected these alterations. We show that RA associates to worse stroke-outcome via exacerbated BBB degradation by decrease of the TJPs claudin-5 and occludin. We identified MMPs-3 and -9 and increased oxidative stress as potential mediators thereof. Increased numbers of resident and peripheral innate immune cells (microglia and macrophages) may in turn contribute to all these effects. Infliximab-treatment restored the phenotype of RA-mice to baseline. Our data provide evidence clearly linking RA to adverse stroke-outcome in mice and indicate an approved TNF-α inhibitor as a potential strategy to reduce stroke-burden in this setting.

Stroke is the second-leading cause of death and the number one cause of permanent disability worldwide¹, with acute ischemic stroke (AIS) accounting for 4 out of 5 cases.

AIS broadly affects many cerebral components, including the blood brain barrier (BBB) – a diffusion barrier consisting of endothelial cells, the basement membrane, pericytes and astrocyte end feet - which segregates the endovascular from the intra-parenchymal space and thereby protects the brain from frequent fluctuations in systemic homeostasis and invasion of peripheral immune cells².

Inflammation is an important pathogenic component of AIS. Post-ischemically, it acts through a multicellular cascade involving both the adaptive and innate immune-systems at the local and systemic level³. Locally, the resident brain immune cells – microglia - undergo activation by damage associated molecular patterns (DAMPs) with consequent secretion of pro-inflammatory cytokines. This in turn can facilitate the invasion of the ischemic brain by peripheral myeloid and lymphoid cells via BBB-degradation⁴,⁵.

Thus, patients suffering from a chronic inflammatory disease could at once experience a higher risk for and worsened outcome of stroke.

¹Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland. ²First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy. ³Gladstone Institute of Neurological Disease; UCSF, San Francisco, CA, USA. ⁴Biomedical Sciences Research Center, Varkiza, Greece. ⁵University Heart Center, University Hospital Zurich, Zurich, Switzerland. ⁶Royal Brompton and Harefield Hospitals Trust, London, UK. ⁷Department of Internal Medicine, Cantonal Hospital Baden, Baden, Switzerland. Correspondence and requests for materials should be addressed to G.G.C. (email: giovanni.camici@uzh.ch)
Rheumatoid arthritis (RA) is an immune-mediated, chronic inflammatory disorder. With a prevalence of ~1%, it ranks among the top 15% of diseases causing disability worldwide. Apart from debilitating articular effects, associated systemic complications reduce median survival by 17 years. Cardiovascular mortality is hereby increased by about 50%.[1,6,11] Particularly, the risk for myocardial infarction (MI) is increased by at least 2-fold and acute coronary syndromes in RA patients are clinically more severe and associate to higher fatality rates.[2,13]

While the epidemiology of MI in RA is well characterized, the one of stroke is less defined with some studies reporting an increased risk[3,14–16] and others finding no association.[17–20] Also, data on stroke outcome are conflicting, with some studies showing increased mortality rates and others not.[21–26] Meanwhile, data on clinical stroke severity and presentation are sparse.

TNF-α inhibitors, such as the monoclonal TNF-α antibody Infliximab, are clinically approved for the treatment of RA which remains active despite therapy with disease modifying anti-rheumatic drugs. TNF-α can play a dual role in stroke, promoting inflammatory stroke progression on one hand and mediating cerebral tolerance to hypoxia and ischemia on the other. Therefore, the potential effect of TNF inhibitors in RA patients with stroke is far from obvious.[27]

We hereby investigated outcome after I/R induced brain injury in a mouse model of RA and assessed for the role of Infliximab in this setting.

**Methods**

**Animals.** Sixteen weeks old male and female TNF-α transgene over-expressing mice on a CBA x C57BL/6 hybrid background were used as a murine model for RA.[28] Briefly, a 2.8 kb fragment of the human TNF-α genomic sequence comprising 0.6 kb of 5′ regulatory sequences, introns and exons up to the stop codon was used for the transgene. The 3′ region of the human TNF-α gene was replaced with that of the human β-globin gene, resulting in TNF-α dysregulation and pathology development.[29]

The RA mouse model exists in two severity degrees, depending on the copy number of the transgene. The more severely affected TG197 line expresses five copies, while the milder TG3647 line expresses only one.[29,30] At 6–8 weeks of age, the TG3647 line develops an arthritic phenotype with 100% penetrance. Symptoms chronically progress over a possible lifespan of about 1 year. Therefore, the line well-reflects chronic, adult-onset RA and allows for the study of advanced stages of RA. Anti-TNF-α treatment was shown to correct the arthritic phenotype of TG3647 mice.[31,32] To reduce post-surgical mortality and suffering, the milder TG3647 mouse line was used in this study. The TG3647 mice will be referred to as RA-mice throughout the manuscript.

Breeding was maintained by crossing transgenic males with wild type (WT) females. Animals were maintained at 24°C under a 12 h light/dark cycle and were fed a normal chow diet with ad libitum access to food and water. Study design and experimental protocols were approved by the institutional animal care committee (License N° TVA 077_2016; Kommission für Tierversuche des Kantons Zürich, Switzerland). All protocols were carried out in accordance with the relevant guidelines and regulations.

**Infliximab treatment.** RA-mice of both sexes were randomly assigned to either weekly intraperitoneal injections of Infliximab (Remicade®, MSD AG, NJ, USA) at a clinically relevant dose (10 mg/kg bodyweight) for 4 weeks between weeks 12 to 16 (RA Infliximab), or an equivalent regimen of distilled water (RA). Wildtype animals received the same vehicle treatment (WT). Infliximab was acquired from the Zurich cantonal pharmacy.

**Clinical scoring.** During the treatment period from week 12 to 16, animals were scored weekly using a clinical score for arthritic symptoms, social behaviour and bodyweight-loss.

The arthritic joint assessment was based on a previously published scoring system[33]: 0 (normal); 1 (edema or reddening of paw and/or ankle joints); 2 (distortion of paw and/or ankle joints); 3 (subluxation or ankyloses of paw and/or ankle joints).

Social behaviour was scored as follows: 0 (normal); 1 (minor changes, less interaction); 2 (burrowing or hiding, reduced mobility, isolation); 3 (no cage exploration, immobility). Finally, bodyweight was scored in this manner: 0 (steady weight or weight gain); 1 (weight loss of ≤5%); 2 (weight loss >5–10%); 3 (weight loss >10%).

Scores from each of the three categories were summed up to obtain the final score.

**Transient Middle Cerebral Artery Occlusion.** Transient Middle Cerebral Artery Occlusion (tMCAO) was performed to induce I/R brain injury, as previously described.[14,34] Briefly, mice were anaesthetized using isoflurane 4% and 1.5% for induction and maintenance respectively. Body temperature was maintained at 37 °C. For analgesia, buprenorphine-HCL (0.1 mg/kg) was infiltrated subcutaneously at the incision site 30 minutes prior to surgery. The common, internal and external carotid arteries were dissected and a 6-0 silicone-coated filament (Doccol Corporation, Sharon, MA, USA) inserted into the common carotid artery and advanced to the origin of the left MCA to induce tMCAO for 45 min. After ischemia, middle cerebral artery (MCA) reperfusion was allowed for 24 h. During this time, animals were carefully observed and received analgesia with buprenorphine-HCL at a dose of 0.1 mg/kg s.c. every 6 hours. After 24 h of reperfusion, mice were sacrificed using an overdose of CO2.

**Stroke Volume.** After euthanasia, mice were perfused with 10 ml of phosphate buffered saline (PBS) and relevant organs were excised. Murine brains were cut into 6 equally spaced (1 mm) coronal sections and immersed in a 2% solution of 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma-Aldrich, Chemie GmbH, Buchs, Switzerland) at 37 °C for 20 min. TTC is a redox indicator, which changes its colour from white to red, as it gets reduced to 1,3,5-triphenylformazan in viable tissues. In metabolically inactive tissues lacking cellular respiration, this reduction does not take place, leaving TTC in its unreacted state. Therefore, the stroke area can be distinguished from viable brain tissue by its white appearance.[35]
Areas of infarction, ipsilateral and contralateral hemisphere volumes were quantified using ImageJ software (Image J, NIH, MD, USA). To correct infarct size measurement for cerebral edema and consequent overestimation, we applied the following formula as previously described\(^7\): Corrected infarct volume = contralateral hemisphere volume - (ipsilateral hemisphere volume - infarct volume). Infarct size was expressed as volume in mm\(^3\).

**Neurological Deficiency Assessment.** Baseline and post-infarction neurological status were assessed by a four-point scale neurological score according to Bederson et al.\(^,^{8,9}\) and the RotaRod test as previously described\(^4,14\). Both tests are composite sensory-motor tests, which take into account motor functions, proprioception, spatial orientation and balance\(^39\). The neurological score test according to Bederson was performed at baseline, 2h and 24 h after reperfusion and consists of the following scores: grade 0, normal neurological function; grade 1, forelimb and torso flexion on and towards the contralateral side upon lifting of the animal by the tail to 1 m above the work surface; grade 2, circling to the contralateral side; grade 3, leaning to the contralateral side at rest; grade 4, no spontaneous motor activity. The RotaRod test was performed at baseline and 24 h after reperfusion. To this purpose, mice were placed on a rotating rod at increasing speed and the time to tendency to fall was measured in seconds. Per animal, three consecutive measurements were performed at each time-point and the best score was used.

**Histology.** Histological procedures were performed as previously described\(^40,41\). Briefly, following euthanasia, mice were exsanguinated by cardiac puncture and transcardially perfused with PBS and 4.0% paraformaldehyde (PFA) (Sigma-Aldrich, Chemie GmbH, Buchs, Switzerland) in PBS at room temperature. The brains were removed and consecutively incubated overnight in 4.0% PFA and afterwards transferred to 30% sucrose in PBS for 36h. Cryoprotected brains were cut into 100-µm thick free-floating sections using a microtome (Leica Jung HN40), pre-treated with proteinase K or 1M HCL for antigen retrieval and immune-blocked with 10% donkey serum. After these steps, they were incubated with primary antibodies at the following dilutions: Iba-1 (1:500; Wako Chemicals, Osaka, Japan), Occludin (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), the endothelial marker CD31 (1:50; BD Pharmingen, Allschwil, Switzerland), claudin-5 (1:200; Abcam, Cambridge, United Kingdom), VE-cadherin (1:200; Abcam, Cambridge, United Kingdom), 4-Hydroxynonenal (4-HNE) (1:200; Abcam, Cambridge, United Kingdom), MMP-3 (1:100; Abcam, Cambridge, United Kingdom) and MMP-9 (1:500; Abcam, Cambridge, United Kingdom) at 4°C overnight, respectively. Secondary antibodies were added at a dilution of 1:750 (Jackson Immunoresearch, West Grove, PA, USA) for 24h at 4°C. Images were acquired using a confocal microscope (Leica SP8; Leica, Wetzlar, Germany). Cells positively stained for the microglial and activated macrophage marker Iba-1, were counted in a specified ipsilateral area (the CA1 hippocampal area) using ImageJ software. Stained areas of claudin-5, occludin, VE-cadherin, MMP-3 and MMP-9 were measured using ImageJ software (Image J, NIH, MD, USA) and normalized to the total endothelial cell surface area assessed by CD31 staining. The area positively stained for 4-HNE on the ipsilateral hemisphere was measured using ImageJ software (Image J, NIH, MD, USA) and expressed as a percentage of the contralateral hemisphere.

BBB permeability was assessed by quantifying endogenous immunoglobulin G (IgG) extravasation. Sections were incubated with Alexa647-conjugated donkey anti-mouse IgG for 24h (1:600; Jackson Immunoresearch, West Grove, USA). IgG-stained area was expressed as a percentage of the contralateral hemisphere.

**Statistical Analysis.** Data were expressed as mean ± standard error of the mean (SEM). All statistical analyses were performed using GraphPad Prism 7 software (GraphPad Software, Inc, La Jolla, CA, USA). Results were confirmed to follow a normal distribution with the Kolmogorov-Smirnov test of normality. Data that passed the normality assumption were analyzed with two-tailed unpaired Student's t-test and data that failed the normality assumption were analyzed with the nonparametric Mann–Whitney test. A probability value (P) below 0.05 was considered statistically significant. For the graphical depiction of p-values in the figures, the following applies: *P < 0.05, **P < 0.01, ***P < 0.001.

**Results**

**RA mice develop a progressive arthritic phenotype which can be averted by Infliximab.** RA mice displayed a progressive increase in the composite clinical score over time. At the age of 12 weeks, RA animals of both the treatment and the control groups showed relatively mild arthritic symptoms. Thereafter, symptom severity steadily increased in the vehicle-injected animals, while Infliximab treatment could blunt the increase (week 14: RA 2.44 ± 0.53, n = 9 vs. RA Infliximab 1.44 ± 0.52, n = 9; p < 0.0001; week 15: RA 3 ± 0.70, n = 9 vs. RA Infliximab 1.33 ± 0.50, n = 9; p < 0.0001; week 16: RA 3.44 ± 0.72, n = 9 vs. RA Infliximab 1.11 ± 0.33, n = 9; p < 0.0001; Fig. 1A). At all time-points, treated and untreated RA animals scored significantly higher than WT animals, where the clinical score remained 0 for the whole duration of the study.

**RA mice display larger strokes and worse neurological function upon I/R brain injury.** Upon tMCAO, we observed significantly larger stroke volumes in RA compared to WT animals (WT: 42.88 ± 3.87 mm\(^3\), n = 12 vs. RA: 68.1 ± 5.26 mm\(^3\), n = 6; P = 0.0024; Fig. 1B,C).

Weekly treatment with Infliximab over 4 weeks, restored stroke volumes in RA animals to levels observed in WTs (RA: 68.1 ± 5.26 mm\(^3\), n = 6 vs. RA Infliximab: 45.8 ± 4.99 mm\(^3\), n = 6; P = 0.0192; WT vs. RA Infliximab; P = NS; Fig. 1B,C).

Neurological performance was significantly impaired in RA compared to WT animals, as assessed by the Bederson test (2h: WT 1.88 ± 0.12, n = 17 vs. RA 2.25 ± 0.13, n = 12; P = 0.0270; 24h: WT 1.24 ± 0.10, n = 17 vs. RA 1.67 ± 0.14, n = 12; P = 0.0075) and the RotaRod test (WT 49.82 ± 4.4s, n = 17 vs. RA 32.3 ± 6.5 s, n = 12; P = 0.0128). Infliximab-treatment improved neurological function in the Bederson (2h: RA 2.25 ± 0.13, n = 12 vs. RA Infliximab 1.5 ± 0.22, n = 6; P = 0.0003; 24h: RA 1.67 ± 0.14, n = 12 vs. RA Infliximab 1 ± 0, n = 6; P = 0.0015;
WT vs. RA Infliximab (all time points); $P = \text{NS}$; Fig. 1D) as well as the RotaRod test (RA: $32.3 \pm 6.5$ s, $n = 12$ vs. RA Infliximab: $67 \pm 7.4$ s, $n = 6$; $P = 0.0001$; WT vs. RA Infliximab; $P = \text{NS}$; Fig. 1E). On a more descriptive note, 2 h after reperfusion, all WT and Infliximab-treated mice had a Bederson score of either 1 or 2, which corresponds to forelimb flexion on the contralateral side or circling to the contralateral side respectively. Meanwhile, 25% of the RA animals scored 3 at 2 h, which corresponds to leaning to the contralateral side even at rest. None of the RA animals displayed only mild neurological symptoms (Bederson score 1) at any time point.

At 24 h post reperfusion, the majority of WT and all of the RA Infliximab animals retained only mild neurological symptoms (Bederson score 1), while 67% of RA animals still displayed circling to the contralateral side (Bederson score 2).
RA mice display increased numbers of microglia and activated macrophages. Microglia as the resident immune cells of the brain, are the first to respond to exposure of damage associated molecular patterns (DAMPs) following ischemia. Upon activation, they can secrete pro-inflammatory cytokines such as TNF-α and IL-1β and thereby exacerbate neuronal injury and paracellular permeability.

Ionized calcium binding adaptor molecule 1 (Iba-1) is a marker for both microglia and activated macrophages. In order to assess the contribution of microglia and invading macrophages (M/M) to the observed stroke phenotype, we have measured Iba-1 as a surrogate for these cells in the ipsilateral hemisphere.

RA animals showed significantly increased numbers of M/M in the stroke area compared to WT mice (WT: 1180 ± 303, n = 8 vs. RA: 1694 ± 280, n = 8; P = 0.0026). Infliximab treatment meanwhile significantly lowered the count of these resident and peripheral immune cells compared to both untreated RA animals and even WT mice (RA: 1694 ± 280, n = 8 vs. RA Infliximab 678 ± 208, n = 8; P < 0.0001; WT: 1180 ± 303, n = 8 vs RA Infliximab 678 ± 208, n = 8; P = 0.0032, Fig. 2A,B).

RA mice display increased BBB disruption and tight junction protein (TJP) degradation. I/R-induced BBB breakdown is characterized by extravasation of large circulating molecules, such as IgG into the affected parenchyma42. A disrupted BBB allows for the formation of vasogenic edema and the invasion of systemic inflammatory cells, which both drive stroke progression. It is thus an important mediator of unfavourable stroke outcome. As to be expected, we observed some IgG extravasation into ischemic hemispheres in all experimental groups, whereas the contralateral hemispheres remained unaffected.

RA mice displayed aggravated BBB disruption upon I/R, as documented by increased extravasation of IgG (WT: 24.33 ± 3.46%, n = 8 vs. RA: 60.06 ± 6.87%, n = 6; P = 0.0002). Infliximab-treatment blunted IgG extravasation to baseline levels (RA: 60.06 ± 6.87%, n = 6 vs. RA Infliximab: 19.72 ± 4.82%, n = 8; P < 0.0001; WT vs. RA Infliximab; P = NS, Fig. 3A,B).

Integrity of the endothelial component of the BBB is regulated by tight and adherens-junctional proteins (TJP). During stroke, paracellular permeability increases due to the degradation of these proteins. Here, we assessed the integrity of the 2 TJP occludin and claudin-5 as well as the adherens junction protein VE-cadherin by immunostaining.

Both claudin-5 and occludin tissue protein levels were lower in the ipsilateral hemispheres of RA compared to WT-animals (claudin-5; WT: 0.79 ± 0.15, n = 8 vs. RA: 0.43 ± 0.07, n = 10; P = 0.0328; Fig. 3C,D/occludin; WT: 0.77 ± 0.06, n = 6 vs. RA: 0.52 ± 0.08, n = 8; P = 0.0284; Fig. 3E,F). VE-cadherin expression was unaltered. The representative images depict a specified area in the ipsilateral hemisphere, where the vasculature appears in green in the top panel (for the endothelial marker CD31) and the respective TJP’s in red or magenta in the middle panel. The bottom panel shows an overlay of the TJP’s with the total endothelial surface, where a reduction of said proteins in the RA animals becomes apparent.

Figure 2. RA associates to increased post-ischemic counts of microglia and activated macrophages. (A) Numbers of microglia and activated macrophages as determined by Iba-1 staining in a specified area of the stroke hemisphere 24 h after tMCAO in WT, RA and RA Infliximab mice. (B) Representative images showing microglia and activated macrophages (red) in the stroke hemispheres of WT, RA and RA Infliximab mice 24 h after tMCAO.
Infliximab-treatment of RA animals restored the expression of claudin-5 (WT: 0.79 ± 0.15, n = 8 vs. RA Infliximab: 1.04 ± 0.14, n = 11; P = NS, Fig. 3C, D) and occludin (WT: 0.77 ± 0.06, n = 6 vs. RA Infliximab: 0.70 ± 0.06, n = 10; P = NS, Fig. 3E, F) to WT levels. Moreover, treatment with Infliximab significantly increased claudin-5 expression compared to vehicle treated RA animals (RA: 0.43 ± 0.07, n = 10 vs. RA Infliximab: 1.04 ± 0.14, n = 11; P = 0.001).

Infliximab-treatment of RA animals restored the expression of claudin-5 (WT: 0.79 ± 0.15, n = 8 vs. RA Infliximab: 1.04 ± 0.14, n = 11; P = NS, Fig. 3C, D) and occludin (WT: 0.77 ± 0.06, n = 6 vs. RA Infliximab: 0.70 ± 0.06, n = 10; P = NS, Fig. 3E, F) to WT levels. Moreover, treatment with Infliximab significantly increased claudin-5 expression compared to vehicle treated RA animals (RA: 0.43 ± 0.07, n = 10 vs. RA Infliximab: 1.04 ± 0.14, n = 11; P = 0.001).

**Figure 3.** RA associates to increased blood brain barrier permeability through decreased tight junction protein levels: (A) Representative images showing endogenous IgG extravasation (red) into the brain parenchyma (green for CD31) 24 h after tMCAO in WT, RA and RA Infliximab mice. (B) Endogenous IgG extravasation 24 h after tMCAO expressed as a percentage of the contralateral hemisphere. (C,E) Representative immunostainings for claudin-5 (red) and occludin (magenta) and CD31 (green) in ipsilateral hemispheres 24 h after tMCAO. (D,F) Quantification of claudin-5 and occludin positive areas normalized to the total endothelial surface area (CD31) in ipsilateral hemispheres of WT, RA and RA Infliximab animals.
RA mice display higher levels of MMP-3 and MMP-9 and increased lipid peroxidation. As potential mediators of increased TJP-degradation, expression levels of MMPs-3 and -9 were evaluated by immunostaining. We found augmented expression of MMP-3 in RA compared to WT animals (WT: 0.31 ± 0.09, n = 6 vs. RA: 1.30 ± 0.25, n = 7; P = 0.0023, Fig. 4A,B). MMP-9 expression levels were also raised in RA compared to WT mice (WT: 0.28 ± 0.05, n = 6 vs. RA: 1.36 ± 0.35, n = 7; P = 0.0106, Fig. 4C,D). Infliximab-treatment blunted MMP-3 (RA: 1.30 ± 0.25, n = 7 vs. RA Infliximab: 0.53 ± 0.09, n = 7; P = 0.0116, Fig. 4A,B) and MMP-9 (RA: 1.36 ± 0.35, n = 7 vs. RA Infliximab: 0.45 ± 0.11, n = 7; P = 0.0254, Fig. 4C,D) levels. The representative images depict a specified area in the ipsilateral hemisphere, where the vasculature appears in green in the top panel (for the endothelial marker CD31) and the respective MMPs in red or magenta in the middle panel. The bottom panel shows an overlay of MMP immunoreactivity with the total endothelial surface, where an increase of said enzymes in the RA animals becomes apparent.

Increased oxidative stress is known to activate MMP-3 and MMP-951. Thus, we assessed for post-ischemic oxidative stress levels by immunostaining for 4-HNE – a marker of lipid peroxidation.

4-HNE levels were increased in RA compared to WT mice (WT: 7.38 ± 0.67%, n = 9 vs. RA: 24.37 ± 3.45%, n = 9; P < 0.0001; Fig. 4E,F). Infliximab-treatment of RA-mice blunted lipid peroxidation (RA: 24.37 ± 3.45%, n = 9 vs. RA Infliximab: 8.53 ± 1.24%, n = 6; P = 0.0005; Fig. 4E,F). The representative images show 4-HNE immunoreactivity (cyan) in the stroke area of WT, RA and RA Infliximab animals.

Discussion

RA is a chronic systemic, immune-mediated inflammatory disorder. Apart from debilitating articular effects, RA associates to a decreased median survival, mainly driven by cardiovascular complications. In particular, the frequency, clinical severity and mortality of acute coronary syndromes are increased12,13. Data on incidence and mortality of stroke in RA patients are more conflicting16,17, while data on clinical severity are sparse. Moreover, the influence of biologicals like Infliximab on stroke outcome in RA patients remains unclear27. Filling this knowl-
edge gap is crucial for designing personalised therapeutic approaches to improve prognosis in these patients. To this end, we aimed to investigate the morphological and functional outcome after I/R brain injury in a RA mouse model.

RA-mice displayed an increased stroke volume by approximately 60% compared to WTs. The physiological relevance of these findings was supported by a greater post-ischemic neurological impairment in RA animals. Infliximab-treatment of RA mice not only improved arthritic symptoms, but also reduced stroke volumes and neurological dysfunction to WT levels, thereby confirming the relevance of inflammation and in particular, of the cytokine TNF-α.

Microglia are the resident brain immune cells and as such, the first line of response to damage associated molecular patterns exposed upon ischemia7. In previous studies, they have been shown to be important secretors of pro-inflammatory cytokines such as TNF-α and IL-1β in the brain54. Furthermore, microglia-derived TNF-α was shown to induce apoptosis in neuronal precursor cells55, attract peripheral immune cells56 and facilitate extravasation of immune cells, platelets, erythrocytes and fibrin by increasing endothelial adhesion molecule expression57,58. Moreover, in an attempt at neo-vascularization upon ischemia, microglia along with endothelial cells and astrocytes increase the generation of matrix metalloproteinases, which in turn contribute to BBB dys-
function by degrading extracellular matrix and tight junction proteins49.

We found increased numbers of activated microglia and macrophages in the stroke hemispheres of RA ani-

mals, when compared to WT. Treatment with Infliximab meanwhile significantly decreased the post-ischemic counts of these cells, both compared to untreated RA animals and WT mice. These findings suggest not only a pertinent role of resident and peripheral immune-cells in mediating the observed stroke phenotype, but also a role for TNF-α in activating and recruiting these cells to the site of injury.

BBB disruption is a hallmark of stroke and a mediator of brain injury and stroke progression50. This notion is supported by data showing BBB-breakdown as early as 30 minutes after ischemia17. Inflammatory cytokines play a crucial role in this respect. Indeed, TNF-α and IL-6 were shown to dose-dependently decrease tight-

and adherens-junction expression in vitro59 and to be increased in ischemic hemispheres of rats after tMCAO53. Furthermore, TNF-α serum- and cerebrospinal fluid-levels are increased in stroke patients and positively corre-
late to stroke severity59.

We found that RA mice display an increased BBB disruption after stroke as compared to WTs. As possible mediators thereof, we describe reduced protein levels of the TJP proteins Claudin-5 and occludin. These transmembrane proteins are the backbone of cerebral endothelial TJs, which uphold three key functions: blocking the paracellular diffusion of blood-borne polar substances; maintenance of cell polarization by preventing lateral diffusion of lipids and membrane proteins and the provision of an intracellular signalling platform. Generally, distancing of these proteins from the cellular borders or decreases in their expression at the TJ clef mediate a loss of junctional integrity and increased paracellular permeability, which in turn directly contributes to vasogenic edema, haem-
orrhagic transformation and increased mortality55,56. Infliximab-treatment of RA mice restored TJP expression to WT levels and in doing so, also conserved BBB integrity as demonstrated by diminished IgG extravasation.

MMPs are proteolytic enzymes degrading all components of the extracellular matrix. In cerebral ischemia, they can mediate early degradation of TJP56,57. The main inducible MMPs in the brain are MMP-3 and MMP-954. Thus, we investigated their putative involvement in the observed BBB-breakdown and found that expression levels of the active enzymes were significantly increased in ischemic hemispheres of RA animals and that these alterations could be reversed by Infliximab, supporting the crucial role of inflammation in post-ischemic MMP expression.

Both MMPs-3 and -9 are secreted in a latent form to undergo activation by nitrosylation or oxidation59, whereas active MMP-3 can also directly activate MMP-9. Additionally, oxidative stress has permeabilizing actions of its own and is subject to inflammatory stimuli. Thus, we investigated oxidative stress levels and showed that
ipsilateral hemispheres of RA animals present significantly more lipid peroxidation – a marker of oxidative stress - as compared to WT, while Infliximab-treatment blunted this increase. This indicates that oxidative stress partially links inflammation to BBB disruption in our model.
The overall-beneficial effects of Infliximab not only underline the pertinence of inflammation to the observed changes in RA mice, but also implicate this drug as a potential modulator of stroke in RA-patients.

One limitation of the herein reported study is represented by the use of vehicle as a control to Infliximab as opposed to using an isotype control antibody. IgG are capable of regulating the immune response through Fc receptor interactions with antibody-bound ligands. Infliximab is a chimeric antibody composed of murine IgG1 and human IgG1, which is isotype-matched to the murine isotype (IgG2a). To our knowledge, the effect of Infliximab on immune responses in vivo has not yet been studied. Thus, using a control antibody of a different species isotype could provide additional information about the specific effects of Infliximab on immune responses in vivo. In conclusion, results from this study contribute additional mechanistic evidence to epidemiological data concerning the link between RA and stroke. They call for further clinical studies in this direction to allow for the design of personalised treatment strategies, which could involve tailored use of biologicals such as Infliximab.

References

1. Donnan, G. A., Fisher, M., Macleod, M. & Davis, S. M. Stroke. Lancet 371, 1612–1623, https://doi.org/10.1016/S0140-6736(08)60694-7 (2008).
2. Fu, Y., Liu, Q., Anrather, J. & Shi, F. D. Immune interventions in stroke. Nat Rev Neurol 11, 524–535, https://doi.org/10.1038/nrneurol.2015.144 (2015).
3. Chamorro, A. et al. The immunology of acute stroke. Nat Rev Neurol 8, 401–410, https://doi.org/10.1038/nrneurol.2012.98 (2012).
4. Neumann, S., Shields, N. J., Balle, T., Chebib, M. & Clarkson, A. N. Innate immunity and inflammation post-stroke: An alpha7-Nicotinic agonist perspective. Int J Mol Sci 16, 29029–29046, https://doi.org/10.3390/ijms161226141 (2015).
5. Rajam, A. et al. Immune responses in stroke: how the immune system contributes to damage and healing after stroke and how this knowledge could be translated to better care? Immunology 154, 363–376, https://doi.org/10.1111/imm.12918 (2018).
6. Cross, M. et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73, 1316–1322, https://doi.org/10.1136/annrheumdis-2013-204627 (2014).
7. Wolfe, F. et al. The mortality of rheumatoid arthritis. Arthritis Rheum 37, 481–494 (1994).
8. Avina-Zubieta, J. A. et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59, 1690–1697, https://doi.org/10.1002/art.20942 (2008).
9. Meune, C., Touze, E., Trinquart, L. & Allano, E. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 48, 1309–1313, https://doi.org/10.1093/rheumatology/kep252 (2009).
10. Wallberg-Jonsson, S., Ohman, M. L. & Dahlqvist, S. R. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 24, 443–451 (1997).
11. Solomon, D. H. et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 65, 1608–1612, https://doi.org/10.1136/ard.2005.030377 (2006).
12. Avina-Zubieta, J. A., Thomas, J., Sadatsafavi, M., Lehman, A. J. & Lacaille, D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71, 1524–1529, https://doi.org/10.1136/annrheumdis-2011-200726 (2012).
13. Mantel, A., Holmqvist, M., Jernberg, T., Wallberg-Jonsson, S. & Askling, J. Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome. Eur Heart J 36, 3413–3422, https://doi.org/10.1093/eurheartj/ehv461 (2015).
14. Sodergren, A., Stegmayr, B., Ohman, M. L. & Wallberg-Jonsson, S. Increased incidence of stroke and impaired prognosis after stroke among patients with seropositive rheumatoid arthritis. Clin Exp Rheumatol 27, 641–644 (2009).
15. Naredshvili, Z., Michaud, K., Hallenbeck, J. M. & Wolfe, F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 59, 1090–1096, https://doi.org/10.1002/art.23935 (2008).
16. Holmqvist, M. et al. Occurrence and relative risk of stroke in incident and prevalent contemporary rheumatoid arthritis. Ann Rheum Dis 72, 541–546, https://doi.org/10.1136/annrheumdis-2013-203871 (2013).
17. Turesson, C., Jarenros, A. & Jacobsson, L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis results from a community based study. Ann Rheum Dis 63, 952–955, https://doi.org/10.1136/annrheumdis-2003.018101 (2004).
18. del Rincon, I. D., Williams, K., Stern, M. P., Freeman, G. L. & Escalante, A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44, 2737–2745 (2001).
19. Solomon, D. H. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, 1303–1307 (2003).
20. Gabriel, S. E., Crowson, C. S. & O’Fallon, W. M. Comorbidity in rheumatoid arthritis. J Rheumatol 26, 2475–2479 (1999).
21. Bjornadl, L. et al. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964–95. J Rheumatol 29, 906–912 (2002).
22. Watson, D. J., Rhodes, T. & Guess, H. A. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 30, 1196–1202 (2003).
23. Goodson, N., Marks, J., Lunt, M. & Symmons, D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 64, 1595–1601, https://doi.org/10.1136/ard.2004.034777 (2005).
24. Allebeck, P. Increased mortality in rheumatoid arthritis. Scand J Rheumatol 11, 81–86 (1982).
25. Mutru, O., Laakso, M., Isoaki, H. & Koota, T. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 290, 1799–1799 (1985).
26. Turesson, C., Jacobsson, L. & Bergstrom, U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 38, 668–674 (1999).
27. Low, A. S. et al. Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol 68, 1337–1345, https://doi.org/10.1002/art.39582 (2016).
28. Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10, 4025–4031 (1991).
29. Li, P. & Schwarz, E. M. The TNF-alpha transgenic mouse model of inflammatory arthritis. Springer Semin Immunopathol 25, 19–33, https://doi.org/10.1007/s00281-003-0125-3 (2003).
30. Zhang, H. et al. NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF-kappaB. J Clin Invest 124, 3200–3214, https://doi.org/10.1172/JCI68901 (2014).
31. Proulx, S. T. et al. Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography. Arthritis Rheum 56, 4024–4037, https://doi.org/10.1002/art.23128 (2007).
54. Zaremba, J. & Losy, J. Early TNF-alpha levels correlate with ischaemic stroke severity. *Arthritis Res 4*, R7, https://doi.org/10.1186/ar430 (2002).

55. Luissint, A. C., Artus, C., Glacial, F., Ganeshamoorthy, K. & Couraud, P. O. Tight junctions at the blood brain barrier: physiological control and clinical implications. *Acta Neurol Scand* 138, 323–333, https://doi.org/10.1111/j.1600-0404.2008.01228.x (2008).

56. Sandoval, K. E. & Witt, K. A. Blood-brain barrier tight junction permeability and ischemic stroke. *Neuropathol Exp Neurol* 33, 290–293, https://doi.org/10.1111/j.1608-3954.2013.01334.x (2013).

57. Yang, Y., Estrada, E. Y., Thompson, J. F., Liu, W. & Rosenberg, G. A. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. *J Cereb Blood Flow Metab* 27, 687–697, https://doi.org/10.1038/sj.jcbfm.9600375 (2007).

58. Yong, V. W., Power, C., Forsyth, P. & Edwards, D. R. Metalloproteinases in biology and pathology of the nervous system. *Nat Rev Neurosci* 2, 502–511, https://doi.org/10.1038/nrn8157 (2001).

59. Gu, Z. et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. *Science* 297, 1186–1190, https://doi.org/10.1126/science.1073634 (2002).

60. Nimmerjahn, F. & Ravetch, J. V. Fc gamma receptors as regulators of immune responses. *Nat Rev Immunol* 8, 34–47, https://doi.org/10.1038/nri2206 (2008).

61. Maini, R. N. et al. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. *Immunol Rev* 144, 195–223 (1995).

62. Feldmann, M., Brennan, F. M. & Maini, R. N. Role of cytokines in rheumatoid arthritis. *Annu Rev Immunol* 14, 397–440, https://doi.org/10.1146/annurev.immunol.14.1.397 (1996).

63. Kollia, G., Douni, E., Kassioti, G. & Kontoyiannis, D. The function of tumour necrosis factor alpha and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. *Ann Rheum Dis* 58(Suppl 1), 132–39 (1999).

64. Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACTION Study Group. *Lancet* 354, 1932–1939 (1999).

**Acknowledgements**

This work was supported by the Swiss National Science Foundation (Drs. Camici [310030_175546], Lüscher [310030_166576] and Ruschitzka [310030_153076]), the Alfred and Annemarie von Sicks Grants for Translational and Clinical Research Cardiology and Oncology to Dr. Camici and the Foundation for Cardiovascular Research–Zurich Heart House. G.G. Camici is the recipient of a Sheikh Khalifa’s Foundation Assistant Professorship at the Faculty of Medicine, University of Zurich. The funding sources had no involvement in the study design, the data collection, analysis or interpretation, the writing of the manuscript or the selection of the journal.
Author Contributions
N.R.B., F.R., T.F.L., J.H.B. and G.G.C. conceived and planned the study. N.R.B., C.D.-C., L.L., M.C., A.A., M.M., M.F.R., S.G. and S.S. performed experiments. G.K. supplied the animal model and lent scientific advice. N.R.B. and G.G.C. analysed the data and drafted the manuscript. All authors revised the article for important intellectual content, reviewed the data and their analyses and approved this article.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019